Endo International plc – (NASDAQ:ENDP) (TSE:ENL) – Leerink Swann issued their Q3 2018 EPS estimates for shares of Endo International in a report released on Tuesday, Zacks Investment Research reports. Leerink Swann analyst A. Fadia anticipates that the company will post earnings per share of $0.76 for the quarter. Leerink Swann has a “Outperform” rating and a $12.00 price target on the stock. Leerink Swann also issued estimates for Endo International’s Q4 2018 earnings at $0.75 EPS and FY2022 earnings at $2.96 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. During the same period in the previous year, the company earned $1.01 EPS. The business’s quarterly revenue was down 11.0% compared to the same quarter last year.
Several other brokerages have also recently issued reports on ENDP. ValuEngine raised shares of Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Goldman Sachs Group assumed coverage on shares of Endo International in a research note on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective for the company. Zacks Investment Research cut shares of Endo International from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Piper Jaffray Companies reissued a “hold” rating and set a $9.00 price objective on shares of Endo International in a research note on Sunday, September 17th. Finally, Mizuho reaffirmed a “buy” rating and set a $12.00 price target (down from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $11.27.
Shares of Endo International (ENDP) traded up $0.03 during midday trading on Thursday, hitting $7.95. 4,318,101 shares of the stock traded hands, compared to its average volume of 5,004,792. Endo International has a one year low of $5.77 and a one year high of $14.45. The stock has a market cap of $1,768.64, a PE ratio of -0.35, a PEG ratio of 2.72 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.
A number of institutional investors have recently made changes to their positions in the stock. Blair William & Co. IL purchased a new position in Endo International in the 2nd quarter valued at about $126,000. Riverhead Capital Management LLC boosted its position in Endo International by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares during the last quarter. Bank of Hawaii purchased a new position in Endo International in the 2nd quarter valued at about $180,000. LMR Partners LLP purchased a new position in Endo International in the 3rd quarter valued at about $148,000. Finally, Flinton Capital Management LLC boosted its position in Endo International by 64.4% in the 2nd quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock valued at $228,000 after buying an additional 7,990 shares during the last quarter. 93.06% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/research-analysts-set-expectations-for-endo-international-plc-s-q3-2018-earnings-endp.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Get a free copy of the Zacks research report on Endo International (ENDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.